Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Novel vaccines for Gram+ pathogens
- Medical need for an S. aureus vaccine
- S. aureus is a challenging vaccine target
- Vaccine approach for S. aureus infections
- Learning from past failures
- Design of next generation S. aureus vaccines
- S. aureus capsular polysaccharides as targets
- S. aureus opsonophagocytic assay (OPA)
- CP5/CP8 polysaccharide conjugates OPA titers
- S. aureus antigens associated with virulence
- Clumping factor A: an important virulence factor
- FBI assay
- Manganese transporter C and S. aureus virulence
- Pfizer’s SA4AG vaccine - Phase 2 clinical study
- Novel vaccines for Gram- pathogens
- N. meningitidis serogroup B: unmet medical need
- Novel approaches to identify MnB antigens (1)
- Novel approaches to identify MnB antigens (2)
- Assessing MnB vaccine immunogenicity/efficacy
- Recently licensed MnB vaccines in the US
- Trumenba and Bexsero vaccines approaches
- Summary
Topics Covered
- Novel vaccines for Gram+ pathogens: S. aureus
- Novel vaccines for Gram- pathogens N. meningitides serogroup B
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Jansen, K. (2015, September 30). Bacterial vaccines in development 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 13, 2024, from https://doi.org/10.69645/SIXG4791.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Kathrin Jansen, Dr. Jansen is an employee and shareholder of Pfizer Inc
Bacterial vaccines in development 2
Published on September 30, 2015
38 min
Other Talks in the Series: Vaccines
Transcript
Please wait while the transcript is being prepared...
0:04
Now, we'll move on to describe vaccines and development against
a highly complex pathogen, Staphylococcus aureus.
This pathogen causes disease by expressing a number of virulence factors.
0:22
S.aureus causes a wide spectrum of diseases ranging from
relatively mild skin infections to life-threatening wound and bloodstream infections.
It is a leading cause of morbidity and mortality
in both healthcare-associated and community settings.
In surgical patients, S.aureus infections
are associated with high morbidity and mortality,
prolongation of hospital stays and an increase in healthcare costs.
We also noted increases in antibiotic resistance,
most notably, methicillin resistance.
There is an alarming increase in community-acquired infections as
well in many settings, including pediatric populations.
I also listed on the slide,
populations that are at high risk of S.aureus infection.
1:20
Now, Staphylococcus aureus is a challenging vaccine target.
It's a highly successful commensal organism,
and about 30 percent of humans are colonized with Staph aureus.
Staph aureus exhibits a diverse array of
virulence factors that facilitate colonization and evasion of host immune responses,
such as toxins and adhesion factors;
it is a master in scavenging nutrients from the host,
it exhibits capsular polysaccharides to evade phagocytosis,
and it also has a number of virulence factors that
interfere with appropriate immune host-mediated immune response.
Staph aureus shows extensive strain diversity.
Most humans actually fail to generate
functional antibodies against S. aureus following natural exposure,
be it by colonization or infection.
The importance of this,
I will describe it a little bit later on.